MX2021009971A - Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. - Google Patents

Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.

Info

Publication number
MX2021009971A
MX2021009971A MX2021009971A MX2021009971A MX2021009971A MX 2021009971 A MX2021009971 A MX 2021009971A MX 2021009971 A MX2021009971 A MX 2021009971A MX 2021009971 A MX2021009971 A MX 2021009971A MX 2021009971 A MX2021009971 A MX 2021009971A
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutical composition
same
method therefor
heterocyclic compound
Prior art date
Application number
MX2021009971A
Other languages
English (en)
Inventor
Qiang Tian
Tongtong Xue
Hongmei Song
Xiaojun Han
Jingyi Wang
Zhonghui Chen
Shuangshuang Duan
Guiying Li
Runfeng Han
Qizheng Sun
Liandong Jing
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of MX2021009971A publication Critical patent/MX2021009971A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

La presente descripción está vinculada con un compuesto heterocíclico, una composición farmacéutica que lo comprende, un método para su preparación, y su uso. Específicamente, el compuesto de la presente descripción está representado por la fórmula (I) y se usa para la prevención o el tratamiento de una enfermedad o afección asociada a la actividad de RET. (ver Fórmula).
MX2021009971A 2019-02-19 2020-02-11 Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. MX2021009971A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910124584 2019-02-19
CN201910437878 2019-05-24
CN201910932095 2019-09-29
PCT/CN2020/074696 WO2020168939A1 (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
MX2021009971A true MX2021009971A (es) 2021-10-13

Family

ID=72143544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009971A MX2021009971A (es) 2019-02-19 2020-02-11 Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.

Country Status (14)

Country Link
US (1) US20220144847A1 (es)
EP (1) EP3929198A4 (es)
JP (1) JP2022521859A (es)
KR (1) KR20210131314A (es)
CN (3) CN113316578B (es)
AU (1) AU2020226422A1 (es)
BR (1) BR112021016299A2 (es)
CA (1) CA3130245A1 (es)
CL (1) CL2021002205A1 (es)
CO (1) CO2021011023A2 (es)
IL (1) IL285378A (es)
MX (1) MX2021009971A (es)
SG (1) SG11202107848TA (es)
WO (1) WO2020168939A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115702154A (zh) * 2020-07-28 2023-02-14 四川科伦博泰生物医药股份有限公司 一种嘧啶类化合物的盐和晶型及其制备方法
KR20230159367A (ko) 2021-03-24 2023-11-21 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 키나아제 약물 내성 돌연변이와 관련된 질병의 치료에있어서의 헤테로사이클릭 화합물의 용도 및 그 방법
CN114235976B (zh) * 2021-11-09 2023-11-03 暨南大学 一种含氮杂环有机化合物中间产物的合成和分析方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200707227B (en) * 2005-02-28 2009-08-26 Japan Tobacco Inc Novel aminopyridine compound with syk inhibitory activity
JP2010208945A (ja) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
JP2013107824A (ja) * 2010-03-17 2013-06-06 Dainippon Sumitomo Pharma Co Ltd 新規単環ピリミジン誘導体
RU2013124395A (ru) * 2010-10-28 2014-12-10 Ниппон Синяку Ко., Лтд. Производное пиридина и лекарственное средство
EP2706852B1 (en) * 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
HRP20231681T1 (hr) 2015-11-02 2024-04-12 Blueprint Medicines Corporation Inhibitori za ret

Also Published As

Publication number Publication date
EP3929198A1 (en) 2021-12-29
CN117263945A (zh) 2023-12-22
IL285378A (en) 2021-09-30
CN113316578A (zh) 2021-08-27
AU2020226422A1 (en) 2021-09-09
EP3929198A4 (en) 2022-11-16
BR112021016299A2 (pt) 2021-10-13
CN113316578B (zh) 2023-10-31
CO2021011023A2 (es) 2021-09-09
CA3130245A1 (en) 2020-08-27
WO2020168939A1 (zh) 2020-08-27
CN117327078A (zh) 2024-01-02
JP2022521859A (ja) 2022-04-12
CL2021002205A1 (es) 2022-04-22
US20220144847A1 (en) 2022-05-12
SG11202107848TA (en) 2021-08-30
KR20210131314A (ko) 2021-11-02

Similar Documents

Publication Publication Date Title
MX2023001689A (es) Inhibidores de bcl-2.
PH12020551821A1 (en) Novel compounds
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
CR20210213A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
CR20210385A (es) Compuestos moduladores de fxr (nr1h4)
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
SG11201907240XA (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
ZA202109193B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MX2021012105A (es) Compuestos de pirrol.
MX2015000903A (es) Derivados de carbamato/urea.
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
ZA202300912B (en) Tyk-2 inhibitor
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.